The stock of SpringWorks Therapeutics Inc (NASDAQ:SWTX) last traded at $46.75, down -0.11% from the previous session.
SWTX stock price is now 6.57% away from the 50-day moving average and 14.73% away from the 200-day moving average. The market capitalization of the company currently stands at $3.52B.
With the price target of $60, Evercore ISI recently initiated with Outperform rating for SpringWorks Therapeutics Inc (NASDAQ: SWTX). On February 05, 2024, Guggenheim recently initiated its ‘Buy’ rating on the stock quoting a target price of $75, while ‘BofA Securities’ rates the stock as ‘Buy’
In other news, Edris Badreddin, Chief Operating Officer sold 20,000 shares of the company’s stock on Mar 03 ’25. The stock was sold for $1,084,592 at an average price of $54.23. Upon completion of the transaction, the Chief Operating Officer now directly owns 169,712 shares in the company, valued at $7.93 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 03 ’25, Chief Executive Officer Islam Saqib sold 49,000 shares of the business’s stock. A total of $2,657,656 was realized by selling the stock at an average price of $54.24. This leaves the insider owning 954,869 shares of the company worth $44.64 million. A total of 3.19% of the company’s stock is owned by insiders.
During the past 12 months, SpringWorks Therapeutics Inc has had a low of $28.21 and a high of $62.00. As of last week, the company has a debt-to-equity ratio of 0.02, a current ratio of 4.33, and a quick ratio of 4.18.
The net profit margin was -115.60% and return on equity was -51.57% for SWTX. The company reported revenue of $49.09 million for the quarter, compared to $21.01 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 133.68 percent.
